Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Debrisoquin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | TMPRSS2 | O15393 | 5/20 | 0.84 |
| ▸ | HTR1A | P08908 | 1/20 | 0.84 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.84 |
| ▸ | MAOA | P21397 | 1/20 | 0.84 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Debrisoquin SCHEMBL11656689 | 1.00 | LMNA (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL122316 | 1.00 | LMNA (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL29390380 | 0.92 | TMPRSS2 (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL309184 | 0.92 | TMPRSS2 (1.00) | LMNAHSD17B10THRBTSHRPMP22 | |
| Debrisoquin SCHEMBL122317 | 0.91 | LMNA (0.83) | LMNAHSD17B10THRBTSHRPMP22 | |
| Guanisoquin SCHEMBL29801607 | 0.81 | LMNA (0.68) | LMNAHSD17B10THRBTSHRPMP22 | |
| Guanisoquin SCHEMBL121149 | 0.81 | LMNA (0.68) | LMNAHSD17B10THRBTSHRPMP22 | |
| SCHEMBL17186394 | 0.78 | TMPRSS2 (0.74) | LMNAHSD17B10THRBTSHRPMP22 | |
| SCHEMBL546055 | 0.78 | NOTUM (0.68) | LMNAHSD17B10THRBTSHRPMP22 | |
| SCHEMBL29560844 | 0.78 | NOTUM (0.68) | LMNAHSD17B10THRBTSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20240402180-A1 | METABOLITE BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PACREATIC CYSTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-12-05 | — | — | US | disclosed |
| US-20240360176-A1 | METHODS FOR TREATMENT AND DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS AND/OR HEPATOCELLULAR CARCINOMA | MARSHALL UNIVERSITY RESEARCH CORPORATION | 2024-10-31 | — | — | US | disclosed |
| US-11958915-B2 | Methods for treatment and diagnosis of non-alcoholic steatohepatitis and/or hepatocellular carcinoma | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| WO-2023049741-A1 | METABOLITE BIOMARKERS FOR DIFFERENTIAL DIAGNOSIS OF PANCREATIC CYSTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-03-30 | — | — | WO | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| EP-4011396-A1 | RELEASABLE CONJUGATES | QuiaPEG Pharmaceuticals AB (SE) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | SLC6A2 3704/4885LMNA 3156/4885HSD17B10 2223/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | SLC6A2 361/4885LMNA 2176/4885HSD17B10 160/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | SLC6A2 3704/4885LMNA 3156/4885HSD17B10 2223/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | SLC6A2 361/4885LMNA 2176/4885HSD17B10 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.